Featured Research

from universities, journals, and other organizations

Controversial Medication May Decrease Spasms For Infants With Epilepsy

Date:
February 3, 2009
Source:
Wiley-Blackwell
Summary:
The antiepileptic drug vigabatrin has been shown to be one of the best treatments against a special form of epilepsy in infants, called infantile spasm. However, its use has been limited in many countries because it has been shown to cause a permanent narrowing of visual fields in approximately 40 percent of adults who have been exposed at school age or later.

The antiepileptic drug vigabatrin (VGB) has been shown to be one of the best treatments against a special form of epilepsy in infants, called infantile spasm. However, its use has been limited in many countries because it has been shown to cause a permanent narrowing of visual fields in approximately 40 percent of adults who have been exposed at school age or later.

A new study published in Epilepsia examined school-aged children who had been treated with VGB in infancy. The findings showed normal visual fields in 15 of the 16 children studied children.

While VGB is an effective drug for infantile spasms, there have been no previous reports on later visual field testing after treatment in infancy. This study used a form of peripheral vision testing, called kinetic perimetry, which is effective in detecting peripheral field defects typical of VGB toxicity, and produces more reliable results in children.

Vigabatrin treatment began at a mean age of 7.6 months, and the mean duration of therapy was 21 months, with a mean cumulative dose of 655 grams. Three of the children had been previously treated with another anti-epileptic drug (AED), five had received only hormonal treatment, and eight children had never been treated with any form of AED.

The findings show that the risk of permanent visual field defects caused by VGB may be lower for treatments in infants than in adults. Results showed that 15 children had normal visual fields and mild visual field loss was observed in one child who had been treated with VGB for 19 months and received a cumulative dose of 572 grams. This frequency is lower than previous observations using kinetic perimetry in older children or adults.

The cumulative VGB doses and treatment durations in the study were, on average, lower than in previous studies, which correspond to the much younger age and weight of the tested patients.

“Our results may encourage doctors to use vigabatrin to treat infantile spasms as the risk for visual field damage may be relatively low in many children compared to the risks caused by continuous seizures,” says Dr. Eija Gaily, co-author of the study.

Visual field testing can be carried out in normally developed children from the age of six years. It is important to note that not all children with normal fields manifest normal results at the first visual field testing because good cooperation and attention are required in order to get reliable results. All abnormal findings in children should always be confirmed by repeating the test.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Eija Gaily, Henna Jonsson, Marjatta Lappi. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia, 2009; 50 (2): 206 DOI: 10.1111/j.1528-1167.2008.01961.x

Cite This Page:

Wiley-Blackwell. "Controversial Medication May Decrease Spasms For Infants With Epilepsy." ScienceDaily. ScienceDaily, 3 February 2009. <www.sciencedaily.com/releases/2009/02/090202175155.htm>.
Wiley-Blackwell. (2009, February 3). Controversial Medication May Decrease Spasms For Infants With Epilepsy. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/02/090202175155.htm
Wiley-Blackwell. "Controversial Medication May Decrease Spasms For Infants With Epilepsy." ScienceDaily. www.sciencedaily.com/releases/2009/02/090202175155.htm (accessed July 23, 2014).

Share This




More Mind & Brain News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Do Obese Women Have 'Food Learning Impairment'?

Do Obese Women Have 'Food Learning Impairment'?

Newsy (July 18, 2014) Yale researchers tested 135 men and women, and it was only obese women who were deemed to have "impaired associative learning." Video provided by Newsy
Powered by NewsLook.com
Does Mixing Alcohol and Energy Drinks Boost Urge To Drink?

Does Mixing Alcohol and Energy Drinks Boost Urge To Drink?

Newsy (July 18, 2014) A new study suggests that mixing alcohol with energy drinks makes you want to keep the party going. Video provided by Newsy
Powered by NewsLook.com
Pot Cooking Class Teaches Responsible Eating

Pot Cooking Class Teaches Responsible Eating

AP (July 18, 2014) Following the nationwide trend of eased restrictions on marijuana use, pot edibles are growing in popularity. One Boston-area cooking class is teaching people how to eat pot responsibly. (July 18) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins